SynthesisVirology journal2025
Prevalence and determinants of virologic failure among HIV patients on ART in Africa: A systematic review and meta-analysis.
Synthesis in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Determinants of virologic failure among adult HIV patients on first-line antiretroviral therapy in health facilities of Awi Zone, northwest Ethiopia: a case-control study.AIDS research and therapy · 2026Article
- How AI responds to common HIV/AIDS questions: ChatGPT versus DeepSeek.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Joint United Nations Programme on HIV/AIDS (UNAIDS) has established the 95-95-95 targets, aiming that by 2030, 95% of individuals on ART will achieve viral suppression. While the number of people receiving ART has increased significantly, there is a lack of comprehensive data on the pooled prevalence of virological failure among people living with HIV in Africa. Therefore, this systematic review and meta-analysis aims to assess the prevalence of virological failure and identify contributing factors within this population.
methodsAn extensive search was carried out using databases such as African Journals Online, PubMed, the Cochrane Library, and Google Scholar to find relevant studies examining virological failure and its influencing factors. To assess variability between studies, the I² statistic was utilized, while Egger's test was employed to detect any signs of publication bias. The overall prevalence of virological failure was estimated using the DerSimonian-Laird random-effects model. Additionally, sensitivity analysis was conducted to determine the robustness of the findings and to identify any studies with results that significantly deviated from the rest.
resultOut of nine articles, the overall pooled prevalence of virological failure was 11.54% (95% CI: 5.950-17.128, I²=30.7%). In the African country, virological failure was associated with ART interruption (POR = 7.09 (95% CI: 2.09, 24.09; I² = 79.5%, P = 0.027)), poor adherence (POR = 9.0 (95% CI: 5.41, 14.96; I² = 0.0%; P = 0.709)), TB/HIV co-infection (POR = 6.17 (95% CI: 1.17-32.42; I² = 89.9%; P = 0.002)), and CD4 count/percentage (POR = 7.70 (1.77, 33.42); I² = 84.4%, P = 0.011)). CONCLUSION AND RECOMMENDATION: Virological failure was found to be relatively high in Africa. Therefore, to accelerate progress toward these goals, policymakers should design and implement mechanisms aimed at improving adherence to antiretroviral therapy (ART), preventing treatment interruptions, and reducing the incidence of opportunistic infections such as TB. Furthermore, we recommend that researchers conduct exploratory studies to identify additional factors associated with virological failure, which could inform more targeted and effective interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.